Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Epidermal Growth Factor Receptor
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Oncogenic Driver Alterations
100%
Median Progression-free Survival
80%
Overall Survival
60%
Median Overall Survival
40%
Clinical Efficacy
40%
Human Epidermal Growth Factor Receptor 2 (HER2)
40%
Chemotherapy
40%
Immune Checkpoint Inhibitors
40%
Programmed Death-ligand 1 (PD-L1)
40%
Tumor Proportion Score
40%
Gene Alteration
40%
KRAS mutant
40%
ROS1
40%
Progression-free Survival
20%
Group Analysis
20%
Targeted Therapy
20%
Smoking History
20%
Significant Predictors
20%
Smoking Status
20%
Expression Level
20%
BRAF V600E mutation
20%
Programmed Death-ligand 1 Expression
20%
Combination Treatment
20%
Clinical Benefit
20%
Oncogene-driven
20%
Multicenter Retrospective Study
20%
Non-small Cell Lung Cancer Patients
20%
Clinical Safety
20%
Routine Clinical Practice
20%
Predictive Biomarker
20%
Treatment-naïve Patients
20%
Molecular Alterations
20%
B-Raf
20%
Immune Checkpoint Inhibitor Therapy
20%
Response to Immunotherapy
20%
First-line Regimen
20%
Multivariate Cox Analysis
20%
Positive Expression
20%
MET Exon 14
20%
Immune Checkpoint Inhibitor Treatment
20%
Immune Checkpoint Inhibitor Monotherapy
20%
Immune Checkpoint Inhibitor Combinations
20%
ROS1 Rearrangement
20%
RET Rearrangement
20%
ALK Rearrangement
20%
Biomarkers for Immunotherapy
20%
Medicine and Dentistry
Immunotherapy
100%
Carcinogenesis
100%
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Progression Free Survival
62%
Overall Survival
62%
Immune Checkpoint Inhibitor
62%
Programmed Death 1 Ligand 1
37%
Neoplasm
25%
Gene Mutation
25%
Biological Marker
12%
Monotherapy
12%
Targeted Therapy
12%
Exon
12%
Proportional Hazards Model
12%
Retrospective Study
12%
Oncogene
12%
Immunotherapy Response
12%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Carcinogenesis
100%
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Progression Free Survival
55%
Overall Survival
55%
Immune Checkpoint Inhibitor
55%
Programmed Death 1 Ligand 1
33%
Neoplasm
22%
Chemotherapy
22%
Monotherapy
11%
Biological Marker
11%
Retrospective Study
11%
Immunology and Microbiology
Immunotherapy
100%
Epidermal Growth Factor
100%
Overall Survival
62%
Progression Free Survival
62%
Immune Checkpoint Inhibitor
62%
Programmed Death 1 Ligand 1
37%
Gene Mutation
25%
Exon
12%
Oncogene
12%
Immunotherapy Response
12%